Regulatory News Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment” July 24, 2026Vol.52 No.29By Claire Marie Porter
Guest Editorial The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection July 24, 2026Vol.52 No.29By Christine D. Berg
FreeObituary Gary Morrow, a pioneer in supportive oncology, dies of prostate cancer complications at 82 July 24, 2026Vol.52 No.29By Leslie Orr
PodcastThe Directors The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the wayKnudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long” July 17, 2026Vol.52 No.28By Paul Goldberg and Claire Marie Porter
Regulatory News FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates July 17, 2026Vol.52 No.28By Sara Willa Ernst
Regulatory News OMB proposal to sideline peer review sparks widespread oppositionNearly 500,000 public comments flood in—here are some highlights July 17, 2026Vol.52 No.28By Claire Marie Porter
Guest Editorial Cancer progress is not reaching everyone. Native Nations must be part of the solution. July 17, 2026Vol.52 No.28By Rodney Haring
Sponsored The future of oncology: Early-career scientists need mentorship and a new academic model July 17, 2026Vol.52 No.28By Marcel van den Brink
News Analysis A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. July 10, 2026Vol.52 No.27By Jacquelyn Cobb
Capitol Hill OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill July 10, 2026Vol.52 No.27By Paul Goldberg
